Engine Biosciences Nabs $10M to Develop AI-Based Drug Discovery Tech

Engine Biosciences has raised $10 million in funding to further develop its artificial intelligence-based drug discovery tool.

DHVC and 6 Dimensions Capital co-led the seed investment in the San Francisco-based company. Joining in the investment were WuXi AppTec, EDBI, Pavilion Capital, Baidu Ventures, WI Harper, and Nest.Bio Ventures. Engine says it has demonstrated that the technology can work for various diseases and cell types; the startup says it has active programs in cancer, neurodegeneration, autoimmune disorders, and skin conditions.

Want more AI, machine learning, and drug discovery content? Network and engage with industry leaders online this June. Learn more.

Engine says it will use the capital to continue work on its technology and build out its staff in San Francisco and Singapore, where it has a second location. The company will also seek partnerships to conduct preclinical studies using its technology.

Photo by Depositphotos.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.